Loading...
•
Mar 31, 2020
Cardiff Oncology Q1 2020 Earnings Report
Trovagene announced first quarter 2020 results, highlighting promising data from clinical programs and a company name change to Cardiff Oncology.
Key Takeaways
Trovagene, Inc., soon to be Cardiff Oncology, reported its first quarter 2020 financial results, with total operating expenses of approximately $4.2 million and a net loss of $4.089 million. The company highlighted promising data from its ongoing clinical trials of onvansertib and announced a company name change and leadership transition.
Announced company name change from Trovagene, Inc. to Cardiff Oncology, Inc.
Presented data from clinical trial in KRAS-mutated metastatic colorectal cancer demonstrating consistent tumor regression.
Expanded Board of Directors with the addition of three industry leaders.
Presented Phase 2 data demonstrating the ability of onvansertib to overcome Zytiga®-resistance and provide clinical benefit for mCRPC patients.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...